Has Dan-Victor Giurgiutiu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,938 in general payments to Dan-Victor Giurgiutiu, MD across 201 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dan-Victor Giurgiutiu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dan-Victor Giurgiutiu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dan-Victor Giurgiutiu, MD

Vascular Neurology · Augusta, GANPI 1649434317

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (36.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Medical Device Business Services, Inc. at 55.3% of the total. Reporting peaked in 2024 at $9,801 and has fallen 85.0% since, to $1,468 in 2025.

$16,938in general payments, 2019–2025

Across 201 payments — averaging $84.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medical Device Business Services, Inc.$9K
Imperative Care, Inc$3K
Johnson & Johnson$2K
Penumbra, Inc.$650
Stryker$368
Balt USA, LLC$287
plus $2K from 37 others

$206,932in research payments, 2019–2025

Across 7 payments — averaging $29,562 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$205K
Penumbra, Inc.$2K

What the payments were for

Consulting fees$6,10236%
Travel & lodging$4,82528%
Food & beverage$5,99135%
Education$200%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medical Device Business Services, Inc.	17	$9,374
Imperative Care, Inc	19	$2,664
Johnson & Johnson(2 entities)	49	$1,645
Penumbra, Inc.	10	$650
Stryker	6	$368
Balt USA, LLC	4	$287
Medtronic(2 entities)	7	$214
UCB, Inc.	5	$142
Sunovion Pharmaceuticals Inc.	17	$141
AstraZeneca(2 entities)	6	$137
Tanabe Pharma America, Inc.	6	$135
Pfizer	7	$131
Amgen	5	$122
SK Life Science, Inc.	4	$106
Jazz Pharmaceuticals Inc.	4	$77
Portola Pharmaceuticals, LLC	3	$73
Microtransponder, Inc.	1	$67
Genentech USA, Inc.	4	$55
Microvention, Inc.	2	$44
Qapel Medical Inc	1	$43
Argenx US, Inc.	1	$31
Biohaven Pharmaceutical Holding Company Ltd.	2	$31
Amylyx Pharmaceuticals, Inc.	1	$28
Chiesi USA, Inc.	1	$27
Takeda Pharmaceuticals U.S.A., Inc.	1	$23
Greenwich Biosciences, Inc.	1	$23
Biogen	1	$22
AbbVie	1	$22
Ceribell, Inc.	1	$20
CSL Behring	1	$20
Teva Pharmaceuticals USA, Inc.	1	$20
Neurelis, Inc.	1	$20
Akcea Therapeutics, Inc.	1	$20
Xeris Pharmaceuticals, Inc.	1	$20
Scientia Vascular	1	$18
Genentech, Inc.	1	$17
Novartis	1	$17
E.r. Squibb & Sons, L.L.C.	1	$17
Otsuka America Pharmaceutical, Inc.	1	$14
Octapharma USA, Inc.	1	$14
Irhythm Technologies, Inc.	1	$13
Route 92 Medical, Inc.	1	$13
Natus Medical Incorporated	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular neurology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$70,814

Medicare patients

142

Services billed

401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Losartan Potassium	17	$92

Paid to pharmacies, not to this prescriber.

Other vascular neurology in Augusta

Nicholas SammondAugusta$15
Diogo HaussenAtlanta$91K
Jaydevsinh DoliaAtlanta$25K
Sourabh LahotiMacon$5K
Sung Bae LeeGainesville$1K
Aaron AndersonAtlanta$266
Ovais InamullahMarietta$201
Shannon StewartSavannah$150
Chuan FanMarietta$144
Kyle GrubbsMarietta$90

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →